Bifogade filer
Patient data from the extension part of Alzinova's phase 1b study with ALZ-101 is being processed
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Alzinova AB (publ) (ticker: ALZ), a Swedish biopharmaceutical company focused on the development of treatments for Alzheimer's disease, announces today that patient data from the extension part of the Phase 1b study is now being processed. Alzinova is processing data collected up to week 42 of the extension part, i.e. patients have been in the phase 1b study for at least 84 weeks.
- Data collection for the 42-week analysis of the extension part of the phase 1b study is now complete.
- Results from the 42-week analysis are expected to be published in late November - December 2024.
“The 42-week analysis in the extension part of our phase 1b study is an important step forward. We look forward to analysing and communicating the results, which will provide us with valuable insights into the long-term safety and efficacy of the vaccine. These data will be central to the planning of our upcoming phase 2 study and our efforts to apply for a Fast Track designation with the FDA. It is also very pleasing to note the great interest in our ongoing study and upcoming results from the major pharmaceutical companies during last week's BIO Europe conference in Stockholm”, says Tord Labuda, CEO of Alzinova AB.
Alzinova is conducting a multi-arm phase 1b study with the vaccine candidate ALZ-101. The company has previously announced that it intends to analyse data collected up to week 42 of the extension arm, i.e. when patients have participated in the phase 1b study for at least 84 weeks. The results of the data analysis from the collected data are now being processed and are expected to be published in late November - December 2024.
About ALZ-101
ALZ-101 is a therapeutic vaccine that targets toxic accumulations of amyloid-beta oligomers in the brain. This is different from other treatments that focus on larger plaques, which can contain both harmful and harmless proteins. By vaccinating with ALZ-101, the body is expected to generate its own antibodies against the harmful oligomers, which can protect the brain's synapses and potentially slow the progression of Alzheimer's disease. Over the past year, Alzinova has reported promising results from the ongoing phase 1b study, indicating a potential positive effect of the drug candidate ALZ-101 in patients with early Alzheimer's disease.
For more information, please contact:
Tord Labuda, CEO
E-mail: tord.labuda@alzinova.com